The use of selected nutrition supplements and complementary and alternative medicine in liver disease

Nutrition in Clinical Practice

Volumn 21, Issue 3, 2006, Pages 255-272

  Hanje, A James ^a   Fortune, Brett ^a   Song, Ming ^b   Hill, Daniell ^b   McClain, Craig ^c,d  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE MEDICINE; EVIDENCE BASED MEDICINE; HUMAN; LIVER DISEASE; MALNUTRITION; REVIEW; SAFETY; TREATMENT OUTCOME;

COMPLEMENTARY THERAPIES; EVIDENCE-BASED MEDICINE; HUMANS; LIVER DISEASES; MALNUTRITION; SAFETY; TREATMENT OUTCOME;

EID: 33750580411     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/0115426506021003255     Document Type: Review

References (212)

1. McClain CJ, Hill DB, Kugelmas M, Marsano L. Nutrition and liver disease. In: Bowman B, Russell RM, eds. Present Knowledge in Nutrition. Washington, DC: ILSI Press; 2001:483-496.
2. Mendenhall C, Roselle GA, Gartside P, Moritz T. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration cooperative studies. Alcohol Clin Exp Res. 1995;19:635-641.
3. Mendenhall CL, Tosch T, Weesner RE, et al. VA cooperative study on alcoholic hepatitis II: prognostic significance of protein-calorie malnutrition. Am J Clin Nutr. 1986;43:213-218.
4. Mendenhall CL, Anderson S, Weesner RE, Goldberg SJ, Krolik KA. Protein-calorie malnutrition associated with alcoholic hepatitis. Am J Med. 1984;76:211-222.
5. Mendenhall CL, Moritz TE, Roselle GA, et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs Cooperative Study. Hepatology. 1993;17:564-576.
6. Mendenhall CL; Moritz TE, Roselle GA, et al. Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment: the VA Cooperative Study Group #275. JPEN J Parenter Enteral Nutr. 1995;19:258-265.
7. Sarin SK, Dhingra N, Bansal A, Malhotra S, Guptan RC. Dietary and nutritional abnormalities in alcoholic liver disease: a comparison with chronic alcoholics without liver disease. Am J Gastroenterol. 1997;92:777-783.
8. Caregaro L, Alberino F, Amodio P, et al. Malnutrition in alco-".. holic and virus-related cirrhosis. Am J Clin Nutr. 1996;63:602-609.
9. McClain CJ, Dryden G, Krueger K. Complementary and Alternative Medicine in Gastroenterology: Textbook of Gastroenterology. 4th ed, Vol 1. Philadelphia, PA: Lippincott Williams & Wilkins; 2003:1135-1146.
10. Eisenberg DM, Kessler DM, Kessler RC, Norlock FE, Calkins DR, Delbanco DL. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med. 1993;328:246-252.
11. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative ■ medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998;280:1569-1575.
12. Krueger KJ, McClain CJ, McClave SA, Dryden GW. Nutritional supplements and alternative medicine. Curr Opin Gastroenterol. 2004;20:130-138.
13. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2000;343:1467-1476.
14. Hill DB, Barve S, Joshi-Barve S, McClain C. Increased monocyte nuclear factor-NF-KB activation and tumor necrosis factor production in alcoholic hepatitis. J Lab Clin Med. 2000;135:387-395.
15. Arteel G, Marsano L, Mendez C, Bentley F, McClain CJ. Advances in alcoholic liver disease. Best Pract Res Clin Gastroenterol. 2003;17:625-647.
16. Schrek R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kB and AP-1 in lymphocytes. EMBO J. 1991;10:2247-2258.
17. Schultze-Osthoff K, Los M, Baeuerle P. Redox signaling by transcription factors NF-kB and AP.-l in lymphocytes. Biochem Pharmacol. 1995;50:735-741.
18. Mandrekar P, Catalano D, Szabo G. Alcohol-induced regulation on nuclear regulatory factor NF-KB in human monocytes. Alcohol Clin Exp Res. 1997;21:988-994.
19. Hill DB, Devalaraja R, Joshi-Barve S, Barve S, McClain CJ. Antioxidants attenuate nuclear factor-kappa B activation and tumor necrosis factor-alpha production in alcoholic hepatits patient monocytes and rat kupfer cells, in vitro. Clin Biochem. 1999;32:563-570.
20. McClain CJ, Mokshagundam SP, Barve SS, et al. Mechanisms of non-alcoholic steatohepatitis. Alcohol. 2004;34:67-79.
21. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003;38:413-419.
22. Crespo J, Cayon A, Fernandez-Gili P, et al. Gene expression of tumor necrosis factor a and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 2001; 34:1158-1163.
23. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial over-growth, intestinal permeability, endotoxaemia, and tumour necrosis factor a in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2001;48:206-211.
24. Pena AD, Leclercq I, Field J, George J, Jones B, Farrell G. NF-KB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology. 2005;129:1663-1674.
25. Lee KS, Buck M, Houghlum K, Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type 1 is mediated by oxidative stress through c-myb expression. J Clin Invest. 1995; 96:2461-2468.
26. Parola M, Leonarduzzi G, Biasi F, et al. Vitamin E dietary supplementation protects against carbon tetrachloride-induced chronic liver damage, and cirrhosis. Hepatology. 1992;16:1014-1021.
27. Liu S, Esposti SD, Yao T, Diehl AM, Zern M. Vitamin E therapy of acute CC14-induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding. Hepatology. 1995; 22:1474-1481.
28. Parola M, Muraca R, Dianzani I, et al. Vitamin E dietary supplementation inhibits transforming growth factor β1 gene expression in the rat liver. FEBS Lett. 1992;308:267-270.
29. Layine JE. Vitamin E treatment of nonakoholic steatohepatitis in children: a pilot study. J Pediatr. 2000;136:734-738.
30. Vajro P, Mandato C, Franzese A, et al. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr: 2004;38:48-55.
31. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-a]cohplic steatohepatitis: a pilot study. Aliment Pharmacol Ther.' 2001;15:1667-1672.
32. Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2004;2: 11Q7-1115.
33. Nanji AA, Yang EK, Fogt F, Sadrzadeh SM, Dannenberg AJ. Medium chain triglycerides and vitamin E reduce the severity of established experimental alcoholic liver disease. J Pharmacol Exp Ther. 1996;277:1694-1700.
34. Butcher GP, Rhodes JM, Walker R, Krasner N, Jackson MJ. The effect of antioxidant supplementation on the serum marker of free radical activity and abnormal serum biochemistry in alcoholic patients admitted for detoxification. J Hepatol. 1993; 19: 105-109.
35. de la Maza MP, Petermann M, Bunout D, Hirsch S. Effects of long-term vitamin E supplementation in alcoholic cirrhotics. J A.m Coll Nutr. 1995;14:192-196.
36. Mezey E, Potter JJ, Rennie-Tankersley L, Caballeria J, Pares A. A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. J Hepatol. 2004;40:40-46.
37. Farinati F, Cardin R, De Maria N, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti HCV-positive hepatitis. J Hepatol. 1995;22:449-456.
38. De Maria N, Colantoni A, Fagiuoli S, et al. Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radic Biol Med. 1996;21:291-295.
39. Shimoda R, Nagashima M, Sakamoto M, et al. Increased formation of oxidative DNA-damage 8-hydroxydeoxyguanosine in human livers with chronic hepatitis. Cancer Res. 1994;54:3171-3172.
40. Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology. 1997;113: 1069-1073.
41. Mahmood S, Yamada G, Niiyama G, et al. Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C. Free Radic Res. 2003;37:781-785.
42. von Herbay A, Stahl W, Niederau C, Sies H. Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study. Free Radic Res. 1997;27:599-605.
43. Look MP, Gerard A, Rao GS, et al. Interferon/antioxidant combination therapy for chronic hepatitis C: a controlled pilot trial. Antiviral Res. 1999;43:113-122.
44. Ideo G, Bellobuono A, Tempini S, et al. Antioxidant drugs combined with alpha-interferon in chronic hepatitis C not responsive to alpha-interferon alone: a randomized, multicentre study. Eur J Gastroenterol Hepatol. 1999;11:1203-1207.
45. Saeian.K, Bajaj JS, Franco J, et al; for the Midwest Hepatitis Study Group. High dose vitamin E supplementation does not diminish ribavirin-associated haemolysis in hepatitis C treatment with combination standard alpha-interferon and ribavirin. Aliment Pharmacol Ther. 2004;20:1189-1193.
46. Andreone P, Fiorino S, Cursaro C, et al. Vitamin E as treatment for chronic hepatitis B: results of a randomized controlled pilot trial. Antiviral Res. 2001;49:75-81.
47. Vallee BL, Wacker WEC, Bartholomay AF, Robin ED. Zinc metabolism in hepatic dysfunction, I: serum zinc concentrations in Laennec's cirrhosis and their validation by sequential analysis. N Engl J Med. 1956;255:403-408.
48. Vallee BL, Wacker WEC, Bartholomay AF, Hoch FLH. Zinc metabolism in hepatic dysfunction, II: correlation of metabolic patterns with biochemical findings. N Engl J Med. 1957;257: 1055-1065.
49. Halsted JA, Hackley B, Rudzki C, Smith JC Jr. Plasma zinc concentration in liver diseases: comparison with normal controls and certain other chronic diseases. Gastroenterology. 1968;54: 1098-1105.
50. Walker BE, Dawson JB, Kelleher J, Losowsky MS. Plasma and urinary zinc in patients with malabsorption syndromes or hepatic cirrhosis. Gut. 1973;14:943-948.
51. McClain CJ, Antonow DR, Cohen DA, Shedlofsky S. Zinc metabolism in alcoholic liver disease. Alcohol Clin Exp Res. 1986;10: 582-589.
52. Dinsmore W, Callender ME, McMaster D, Todd SJ, Love AH. Zinc absorption in alcoholics using zinc-65. Digestion. 1985;32: 238-242.
53. Valberg LS, Flanagan PR, Ghent CN, Chamberlain MJ. Zinc absorption and leukocyte zinc in alcoholic and nonalcoholic cirrhosis. Dig Dis Sci. 1985;30:329-333.
54. Kahn AM, Helwig HL, Redeker AG, Reynolds TB. Urine and serum zinc abnormalities in disease of the liver. Am J Clin Pathol. 1965;44:426-435.
55. Bode JC, Hanisch P, Henning H, Koenig W, Richter F-W, Bode C. Hepatic zinc content in patients with various stages of alcoholic liver disease and in patients with chronic active and chronic persistent hepatitis. Hepatology. 1988;8:1605-1609.
56. Kang YJ, Zhou Z. Zinc prevention and treatment of alcoholic liver disease. Mol Aspects Med. 2005;26:391-404.
57. Kessova I, Cederbaum Al. CYP2E1: biochemistry, toxicology, regulation and function in ethanol-induced liver injury. Curr Mol Med. 2003;3:509-518.
58. Nanji AA, Zhao S, Sadrzadeh SM, Dannenberg AJ, Tahna SR, Waxman DJ. Markedly enhanced cytochrome P450 2E1 induction and lipid peroxidation is associated with severe liver injury in fish-oil-ethanol-fed rats. Alcohol Clin Exp Res. 1994;18:1280-1285.
59. Morgan K, French SW, Morgan TR. Production of a cytochrome P450 2E1 transgenic mouse and initial evaluation of alcoholic liver damage. Hepatology. 2002;36:122-134.
60. Morimoto M, Hagbjork AL, Wan YJ, et al. Modulation of experimental alcohol-induced liver disease by cytochrome P450 2E1 inhibitors. Hepatology. 1995;21:1610-1617.
61. Das I, Burch RE, Hahn HK. Effects of zinc deficiency on ethanol metabolism and alcohol and aldehyde dehydrogenase activities. J Lab Clin Med. 1984;104:610-617.
62. Zhou Z, Wang L, Song Z, Saari JT, McClain CJ, Kang YJ. Zinc supplementation prevents alcoholic liver disease in mice through attenuation of oxidative stress. Am J Pathol. 2005;166:1681-1690.
63. Hoek JB, Cahill A, Pastorino JG. Alcohol and mitochondria: a dysfunctional relationship. Gastroenterology. 2002;122:2049-2063.
64. Kojima-Yuasa A, Ohkita T, Yukami K, et al. Involvement of intracellular glutathione in zinc deficiency-induced activation of he'patic stellate cells. Chem Biol Interact. 2003;146:89-99.
65. McClain CJ, Song Z, Barve SS, Hill DB, Deaciuc I. Recent advances in alcoholic liver disease, IV: dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol. 2004;287:G497-G502.
66. Zhou Z, Wang L, Song Z, Lambert JC, McClain CJ, Kang YJ. A critical involvement of oxidative stress in acute alcohol-induced hepatic TNF-alpha production. Am J Pathol. 2003;163:1137-1146.
67. Lambert JC, Zhou Z, Wang L, Song Z, McClain CJ, Kang YJ. Prevention of alterations in intestinal permeability is involved in zinc inhibition of acute ethanol-induced liver damage in mice. J Pharmacol Exp Ther. 2003;305:880-886.
68. Weismann K, Christensen E, Dreyer V. Zinc supplementation in alcoholic cirrhosis: a double-blind clinical trial. Acta Med Scand. 1979;205:361-366.
69. Cesur S, Cebeci SA, Kavas GO, Yilmaz N, Buyukkagnici DI. Serum copper and zinc concentrations in patients with chronic hepatitis C. J Infect. 2005;51:35-37.
70. Cesur S, Cebeci SA, Kavas GO, Aksaray S, Tezeren D. Serum copper and zinc concentrations in patients with chronic hepatitis B.J Infect. 2005;51:38-40.
71. Meram I, Sirmatel F, Ahi S, Tarakcioglu M. Plasma copper and zinc levels in chronic viral hepatitis. Saudi Med J. 2004;25: 1066-1069.
72. Loguercio C, De Girolamo V, Federico A, et al. Trace elements and chronic liver diseases. J Trace Elem Med Biol. 1997;11:158-161.
73. Nagamine T, Takagi H, Hashimoto Y, et al. The possible role of zinc and metallothionein in the liver on the therapeutic effect of IFN-alpha to hepatits C patients. Biol Trace Elem Res. 1997;58: 65-76.
74. Pramoolsinap C, Promvanit N, Komindr S, Lerdverasirikul P, Srianujata S. Serum trace metals in chronic viral hepatitis and hepatocellular carcinoma in Thailand. J Gastroenterol. 1994;29: 610-615.
75. Takagi H, Nagamine T, Abe T, et al. Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C. J Viral Hepat. 2001;8:367-371.
76. Ko WS, Guo CH, Hsu GS W, Chiou YL, Yeh MS, Yaun SR. The effect of zinc supplementation on the treatment of chronic hepatitis C patients with interferon and ribavirin. Clin Biochem. 2005;38:614-620.
77. Butterworth RF. The neurobiology of hepatic encephalopathy. Semin Liver Dis. 1996;16:235-244.
78. Riggio O, Merli M, Capocaccia L, et al. Zinc supplementation reduces blood ammonia and increases liver ornithine transcar-bamylase activity in experimental cirrhosis. Hepatology. 1992; 16:785-789.
79. Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Lancet. 1984;2:493-495.
80. Riggio O, Ariosto F, Merli M, et al. Short-term oral zinc supplementation dogs not improve chronic hepatic encephalopathy: results of a double-blind crossover trial. Dig Dis Sci. 1991;36: 1204-1208.
81. Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology. 1996;23:1084-1092.
82. Bresci G, Parisi G, Banti S. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. Eur J Med. 1993;2:414-416.
83. Roberts EA, Schilsky ML. AASLD guideline: a practice guideline on Wilson disease. Hepatology. 2003;37:1475-1492.
84. Brewer GJ, Yuzbasiyan-Gurkan V, Young AB. Treatment of Wilson's disease. Semin Neurol. 1987;7:209-220.
85. Brewer GJ, Hill GM, Prasad AS, Cossack ZT, Rabbani P. Oral zinc therapy for Wilson's disease. Ann Intern Med. 1983;99:314-319.
86. Brewer GJ, Dick RD, Johnson VD, Brunberg JA, Kluin KJ, Fink JK. Treatment of Wilson's disease with zinc, XV: long-term follow-up studies. J Lab Clin Med. 1998;132:264-278.
87. Valta K, Valta P, Hockerstedt K, Lindgren L. Magnesium depletion in chronic terminal liver cirrhosis. Clin Transplant. 2002;16:325-328.'
88. Cohen L. Magnesium and liver cirrhosis: a hypothesis. Magnesium. 1985;4:1-4.
89. Patrick L. Nonalcoholic fatty liver disease: relationship to insulin sensitivity and oxidative stress: treatment approaches using vitamin E, magnesium and betaine. Altern Med Rev. 2002;7: 276-291
90. Rosolva H, Mayer O, Reaven G. Effect of variations in plasma magnesium concentration on resistance to insulin-mediated glucose disposal in nondiabetic subjects. J Clin Endocrinol Metab. 1997;82:3783-3785.
91. McNair P, Christiansen C, Madsbad S, et al. Hypomagnesemia, a risk factor in diabetic retinopathy. Diabetes. 1978;27:1075-1077.
92. Barbagallo M, Gupta RK, Bardicef M, Resnick LM. Altered ionic effects of insulin in hypertension: role of basal ion levels in determining cellular responsiveness. J Clin Endocrinol Metab. 1997;82:1761-1765.
93. Nadler JL, Buchanan T, Natarajan R, Antonipillai I, Bergman R, Rude R. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension. 1993;21:1013-1019.
94. Yajnil CS, Smith RF, Hockaday TD, Ward NI. Fasting plasma magnesium concentrations and glucose disposal in diabetes. "BMJ (Clin Res Ed). 1984;288:1032-1034.
95. Rodriguez-Hernandez H, Gonzalez JL, Rodriguez-Moran M, Guerrero-Romero F. Hypomagnesemia, insulin resistance, and non-alcoholic steatohepatitis in obese subjects. Arch Med Res. 2005;36:362-366.
96. Aagaard NK, Andersen H, Vilstrup H, Clausen T, Jakobsen J, Dorup I. Magnesium supplementation and muscle function in patients with alcoholic liver disease: a randomized, placebo-controlled trial. Scand J Gastroenterol. 2005;40:972-979.
97. Lu SC, Huang ZZ, Yang H, Mato JM, Avila MA, Tsukamoto H. Changes in methionine adenosyltransferase and S-adenosylme-thionine homeostasis in alcoholic rat liver. Am J Physiol Gastrointest Liver Physiol. 2000;279:G178-G185.
98. Avila MA, Garcia-Trevijano ER, Martinez-Chantar ML, et al. S-adenosylmethionine revisited: its essential role in the regulation of liver function. Alcohol. 2002;27:163-167.
99. McClain CJ, Hill DB, Song Z, et al. Adenosylmethionine, cytokines, and alcoholic liver disease. Alcohol. 2002;27:185-192.
100. Mato JM, Alvarez L, Ortiz P, Pajares MA. S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacol Ther. 1997;73:265-280.
101. Chiang PK, Gordon RK, Tal J, et al. S-adenosylmethionine and methylation. FASEB J. 1996;10:471-480.
102. Hoffman DR, Marion SW, Cornatzer WE, Duerre JA. S-adenosylmethionine and S-adenosylhomocysteine metabolism in isolated rat liver: effects of L-methionine, L-homocysteine, and adenosine. J Biol \Chem. 1980;255:10822-10827.
103. Horowitz JH, Rypins EB, Henderson JM, et al. Evidence for impairment of transsulfuration pathway in cirrhosis. Gastroenterology. 1981;81:668-675.
104. Cabrero C, Duce AM, Ortiz P, Alemany S, Mato JM. Specific loss of high molecular weight form of S-adenosyl-L-methionine synthetase in human liver cirrhosis. Hepatology. 1988;8:1530-1534.
105. Corrales F, Gimenez A, Alvarez L, et al. S-adenosylmethionine treatment prevents carbon tetrachloride-induced S-adenosylmethionine synthetase inactivation and attenuates liver injury. Hepatology. 1992;16:1022-1027.
106. Varela-Moreiras G, Alonso-Aperte E, Rubio M, et al. Carbon tetrachloride-induced hepatic injury is associated with global DNA hypomethylation and homocysteinemia: effect of S-adenosylmethionine treatment. Hepatology. 1995;22:1310-1315.
107. Song Z, Zhou Z, Chen T, et Si. S-adenosylmethionine (SAMe) protects against acute alcohol induced hepatotoxicity in mice. J Nutr Biochem. 2003;14:591-597.
108. Chawla RK, Lewis FW, Kutner MH, Bate DM, Roy RG, Rudman D. Plasma cysteine, cystine, and glutathione in cirrhosis. Gastroenterology. 1984;87:770-776.
109. Lieber CS, Casine A, Do Carli LM, Lowe N, Sasaki R, Leo MA. S-adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon. Hepatology. 1990;11:165-172.
110. Sanchez-Gongora E, Ruiz F, Mingorance J, An W, Corrales FJ, Mato JM. Interaction of liver methionine adenosyltransferase with hydroxyl radical. FASEB J. 1997;11:1013-1019.
111. Hirano T, Kaplowitz N, Tsukamoto H, Kamimura S, Fernandez-Checa JC. Hepatic mitochondrial glutathione depletion and progression of experimental alcoholic liver disease in rats. Hepatology. 1992;16:1423-1427.
112. Loguercio C, Nardi G, Argenzio F, et al. Effect of S-adenosyl-L- methionine administration on red blood cell cysteine and glutathione levels in alcoholic patients with and without liver disease. Alcohol Alcohol. 1994;29:597-604.
113. Frezza M, Surrenti C, Manzillo G, Fiaccadori F, Bortolini M, Di Padova C. Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis: a double-blind, placebo-controlled study. Gastroenterology. 1990;99:211-215.
114. Nicastri PL, Diaferia A, Tartagni M, Loizzi P, Fanelli M. A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. Br J Obstet Gynaecol. 1998;105:1205-1207.
115. Frezza M, Centini G, Cammareri G, Le Grazie C, Di Padova C. S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy: results of a controlled clinical trial. Hepato-gastroenterology. 1990;2:122-125.
116. Mato JM, Camara J, Fernandez de Paz J, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30:1081-1089.
117. Craig SA. Betaine in human nutrition. Am J Clin Nutr. 2004; 80:539-549.
118. Song Z, Zhou Z, Uriarte S, et al. S-adenosylhomocysteine sensitizes to TNF-alpha hepatotoxicity in mice and liver cells: a possible etiological factor in alcoholic liver disease. Hepatology. 2004;40:989-997.
119. Kim SK, Kim YC, Kim YC. Effects of singly administered betaine on hepatotoxicity of chloroform in mice. Food Chem Toxicol. 1998;36:655-661.
120. Kim SK, Kim YC. Attenuation of bacterial lipopolysaccharide-induced hepatotoxicity by betaine or taurine in rats. Food Chem Toxicol. 2002;40:545-549.
121. Junnila M, Barak AJ, Beckenhauer HC, Rahko T. Betaine reduces hepatic lipidosis induced by carbon tetrachloride in Sprague-Dawley rats. Vet Hum Toxicol. 1998;40:263-266.
122. Ji C, Kaplowitz N. Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice. Gastroenterology. 2003;124:1488-1499.
123. Barak AJ, Beckenhauer HC, Mailliard ME, Kharbanda KK, Tuma DJ. Betaine lowers elevated s-adenosylhomocysteine levels in hepatocytes from ethanol-fed rats. J Nutr. 2003;133:2845-2848.
124. Lieber CS, Robins SJ, Leo MA. Hepatic phosphatidylethano-Iamine methyltransferase activity is decreased by ethanol and increased by phosphatidylcholine. Alcohol Clin Exp Res. 1994; 18:592-595.
125. Lee TD, Sadda MR, Mendler MH, Bottiglieri T, Kanel G, Mato JM, Lu SC. Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis. Alcohol Clin Exp Res. 2004;28:173-181.
126. Attwood JT, Yung RL, Richardson BC. DNA methylation and the regulation of gene transcription. Cell Mol Life Sci. 2002;59: 241-257.
127. Antequera F. Structure, function and evolution of CpG island promoters. Cell Mol Life Sci. 2003;60:1647-1658.
128. McBride AE, Silver PA. State of the arg: protein methylation at arginine comes of age. Cell. 2001;106:5-8.
129. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dwornic-zak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demeth-ylation or gene transfer. Oncogene. 2001;20:5865-5877.
130. Hopkins-Donaldson S, Ziegler A, Kurtz S, et al. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ. 2003;10:356-364.
131. Zhu X, Song J, Mar MH, Edwards LJ, Zeisel SH. Phosphati-dylethanolamine N-methyltransferase (PEMT) knockout mice have hepatic steatosis and abnormal hepatic choline metabolite concentrations despite ingesting a recommended dietary intake of choline. Biochem J. 2003;370(pt 3):987-993.
132. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol. 2001;96:2711-2717.
133. Luper S. A review of plants used in the treatment of liver disease: part 1. Altern Med Rev. 1998;3:410-421.
134. Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 1998;93:139.
135. Vogel G, Tuchweber B, Trost W, Mengs U. Protection by silibinin against Amanita phalloides intoxication in beagles. Toxicol Appl Pharmacol. 1984;73:355.
136. Ferenci P, Dragosies B, Dittrich H, Le Grazie C, Di Padova C. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989;9:105.
137. Mira ML, Azevedo MS, Manso C. The neutralization of hydroxyl radical by silibin, sorbinil and bendazac. Free Radic Res Com-mun. 1987;4:125-129.
138. Mira L, Silva M, Manso CF. Scavenging of reactive oxygen species by silibinin dihemisuccinate. Biochem Pharmacol. 1994; 48:753-759.
139. Valenzuela A, Aspillaga M, Vial S, Guerra R. Selectivity of silymarin on the increase of the glutathione content in different tissues of the rat. Planta Med. 1989;55:420-422.
140. Muzes G, Deak G, Lang I, Nekam K, Gergely P, Feher J. Effect of the biflavonoid silymarin on the in vitro activity and expression of superoxide dismutase (SOD) enzyme. Acta Physiol Hung. 1991;78:3-9.
141. Varga Z, Czompa A, Kakuk G, Antus S. Inhibition of the superoxide anion release and hydrogen peroxide formation in PMNLs by flavonolignans. Phytother Res. 2001;15:608-612.
142. Saliou C, Rihn B, Cillard J, Okamoto T, Packer L. Selective inhibition of NF-kappaB activation by the flavonoid hepatopro-tector silymarin in HepG2: evidence for different activating pathways. FEBS Lett. 1998;440:8-12.
143. Schumann N, Prockl J, Kiemer AK, Vollmar AM, Bang R, Tiegs G. Silibinin protects mice from T-cell dependent liver injury. J Hepatol. 2003;39:333-340.
144. Bosisio E, Benelli C, Pirola O. Effect of the flavonolignans of Silybum marianum L. on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. Pharmacol Res. 1992; 25:147-154.
145. Schriever H, Kramer U, Rutkowski G, Borgis KJ. Influence of silibin dihemisuccinate on fatty acid synthesis in rat liver. Arzneimittelforschung. 1979;29:524-526.
146. van Pelt JF, Verslype C, Crabbe T, Zaman Z, Fevery J. Primary human hepatocytes are protected against prolonged and repeated exposure to ethanol by silibinin-dihemisuccinate. Alcohol Alcohol. 2003;38:411-414.
147. Lieber CS, Leo MA, Cao Q, DeCarli LM. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol. 2003;37:336-339.
148. Fuchs EC, Weyhenmeyer R, Weiner OH. Effects of silibinin and of a- synthetic analoge on isolated rat hepatic stellate cell and myofibroblasts. Arzneimittelforschung. 1997;47:1383-1387.
149. Magliulo E, Carosi PG, Minoli L, Gorini S. Studies on the regenerative capacity of the liver in rats subjected to partial hepatectomy and treated with silymarin. Arzneimittelforschung. 1973;23(suppl):161-167.
150. Pares A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol. 1998;28:615-621.
151. Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, Zilli M. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol. 1997;26:871-879.
152. Levy C, Seeff LD, Lindor KD. Use of herbal supplements for chronic liver disease. Clin Gastroenterol Hepatol. 2004;2:947-956.
153. Yoshikawa M, Matsui Y, Kawamoto H, et al. Effects of glycyr-rhizin on immune-mediated cytotoxicity. J Gastroenterol Hepatol. 1997;12:243-248.
154. Shiki Y, Ishikawa Y, Shirai K, Saito Y, Yoshida S. Effect of glycyrrhizin on lysosomes labilization by phospholipase A2. Am J Chin Med. 1986;14:131-137.
155. Shiki Y, Shirai K, Saito Y, Yoshida S,' Mori Y, Wakashin M. Effect of glycyrrhizin on lysis of hepatocytes membranes induced by anti-liver cell membrane antibody. J Gastroenterol Hepatol. 1992;7:12-16.
156. Crance JM, Leveque F, Biziagos E, van Cuyck-Gandre H, Jouan A, Deloince R. Studies on mechanism of action of glycyrrhizin against hepatitis A virus replication in vitro. Antiviral Res. 1994;23:63-76.
157. van Rossum TG, Vulto AG, de Man RA, Brouwer JT, Schalm SVV. Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Then 1998;12:199-205.
158. Okamoto T. The protective effect of glycyyrhizin on anti-Fas antibody-induced hepatitis in mice. Eur J Pharmacol. 2000;387: 229-232.
159. Jeong HG, You HO, Park SJ, et al. Hepatoprotective effects of 18β-glycyrrhetinic acid on carbon tetrachloride-induced liver injury: inhibition of cytochrome P450 2E1 expression. Pharmacol Res. 2002;46:221-227.
160. Abe N, Ebina T, Ishida N. Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice. Microbiol Immunol. 1982;26: 535-539.
161. Abe M, Akbar SK MD, Hasebe A, Horiike N, Onji M. Glycyrrhizin enhances interleukin-10 production by liver dendritic cells in mice with hepatitis. J Gastroenterol. 2003;38:962-967.
162. Suzuki H, Ohta Y, Takino T, Fujisawa \K, Hirayama C. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis. Asian Med J. 1983;26:423-438.
163. Arase Y, Ikeda K, Murashima N, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer. 1997;79: 1494-1500.
164. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990;12:671-675.
165. Tarao K, Takemiya S, Tamai S, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransaminase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer. 1997; 79:688-694.
166. Miyake K, Tango T, Ota Y, et al. Efficacy of Stronger Neo-Minophagen C compared between two doses administered three times a week on patients with chronic viral hepatitis. J Gastroenterol Hepatol. 2002;17:1198-1204.
167. Fujiyama S, Chikazawa H, Honda Y, et al. Treatment of chronic active hepatitis C with interferon-alpha 2b-alone and in combination with Stronger Neo Minophagen C. Biother Jpn. 1998;12: 1495-1513.
168. Suzuki Y, Ikeda K, Saitoh S, et al. A prospective randomized administration of Stronger Neo Minophagen C as an adjuvant therapy for chronic hepatitis type C treated with interferon. Acta Hepatol Jpn. 1996;37:363-367.
169. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet. 1987;2:821-824.
170. Van Rossum TG, De Jong FH, Hop WC, Boomsma F, Schalm SW. Chronic hepatitis C and portal hypertension: diagnosis, treatment with interferon, glycyrrhizin or propanolol: "pseudo-aldosteronism" induced by intravenous glycyrrhizin treatment of chronic hepatitis.C patients. J Gastroenterol Hepatol. 2001; 16:789-795.
171. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm. 2000;57:1221-1227.
172. Shimizu I, Ma YR, Mizobuchi Y, et al. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology. 1999;29:149-160.
173. Yamashiki M, Nishimura A, Suzuki H, Sakaguchi S, Kosaka Y. Effects of the Japanese herbal medicine "Sho-saiko-to" (TJ-9) on in vitro interleukin-10 production by peripheral blood mononuclear cells of patients with chronic hepatitis C. Hepatology. 1997;25:1390-1397.
174. Oka H, Yamamoto S, Kuroki T, et al. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer. 1995;75:743-749.
175. Hirayama C, Okumura M, Tanikawa K, Yano M, Mizuta M, Ogawa N. A multicenter randomized controlled clinical trial of Sho-saiko-to in chronic active hepatitis. Gastroenterol Jpn. 1989; 24:715-719.
176. Katou, K, Mori K. Autoimmune hepatitis with drug-induced pneumonia due to Sho-saiko-to. Nihon Kokyuki Gakkai Zasshi. [Jpn J Thorac Dis). 1999;37:641-646.
177. Murakami K, Okajima K, Sakata K, Takatsuki K. A possible mechanism of interstitial pneumonia during interferon therapy with sho-saiko-to. Nihon Kyobu Shikkan Gakkai Zasshi [Jpn J Thorac Dis]. 1995;33:389-394.
178. Liu J, Lin H, Mcintosh H. Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review. J Viral Hepatol. 2001;8:358-366.
179. Lee CD, Ott M, Thyagarajan SP, Shafritz DA, Burk RD, Gupta S. Phyllanthus amarus down-regulates hepatitis B virus mRNA transcription and replication. Eur J Clin Invest. 1996;26:1069-1076.
180. Chan HLY, Sung JJY, Fong AML, et al. Double-blinded placebo-controlled study of Phyllanthus urinaris for the treatment of chronic hepatitis B. Aliment Pharmacol Ther. 2003;18:339-345.
181. Vaidya AB, Antarkar DS, Doshi JC, et al. Picrorrhiza kurroa (Kutaki) Royle ex Benth as a hepatoprotective agent: experimental and clinical studies. J Postgrad Med. 1996;42:105-108.
182. Ansari RA, Tripathi SC, Patnaik GK, Dhawan BN. Antihepato-toxic properties of picroliv: an active fraction from rhizomes of Picrorrhiza kurroa. J Elhnopharmacol. 1991;34:61-68.
183. Batey R, Cao Q, Pang G, Clancy RL. Effects of CH-100, a Chinese herbal medicine, on acute concanavalin A-mediated ■ hepatitis in control and alcohol-fed rats. Alcohol Clin Exp Res. 2000;24:852-858.
184. Batey RG, Bensoussan A, Fan YY, Bollipo S, Hossain MA. Preliminary report of a randomized, double-blinded placebo-controlled trial of a Chinese herbal medicine preparation CH-100 in the treatment of chronic hepatitis C. J Gastroenterol Hepatol. 1998;13:244-247.
185. Wang L, Wnag BE, Xiao PG, Qiao YJ, Tan XH. Effects of herbal compound 861 on human hepatic stellate cell proliferation and activation. World J Gastroenterol. 2004;10:2831-2835.
186. Jia JD, Wang BE, Dong Z, Cui L, Zhu JX, Che JT. The effect of herbal compound 861on mRNA levels for type I, III, and TV collagens and TGF in immune complex rat liver fibrosis. Chin J Hepatol. 1996;4:214-216.
187. Yin SS, Wang BE, Wang TL, Jia JD, Qian LX. The effect of Cpd 861 on chronic hepatitis B related fibrosis and early cirrhosis: a randomized, double blind, placebo controlled clinical trial. Zhon-ghua Gan Zang Bing Za Zhi. 2004;12:467-470.
188. Yang F, de Villiers WJS, McClain CJ, Varilek GW. Green tea polyphenols block endotoxin-induced tumor necrosis factor-a production and lethality in a murine model. J Nutr. 1998;128: 2334-2340.
189. Fiorini RN, Donovan JL, Rodwell D, et al. Short-term administration of (-)-epigallocatechin gallate reduces hepatic steatosis and protects against warm hepatic ischemia/reperfusion injury in steatotic mice. Liver Transplant. 2005;11:298-308.
190. Sakata R, Ueno T, Nakamura T, Sakamoto M, Torimura T, Sata M. Green tea polyphenol epigallocatechin-3-gallate inhibits platelet-derived growth factor-induced proliferation of human hepatic stellate cell line LI90. J Hepatol. 2004;40:52-59.
191. Lin CF, Wong KL, Wu RC, Huang TC, Liu CF. Protection by hot water extract of Panax notoginseng on chronic ethanol-induced 'hepatotoxicity. Phytother Res. 2003;17:1119-1122.
192. Park WH, Lee SK, Kim CH. A Korean herbal medicine, Panax notoginseng, prevents liver fibrosis and hepatic microvascular dysfunction in rats. Life Sci. 2005;76:1675-1690.
193. Clouatre DL. Kava kava: examining new reports of toxicity. Toxicol Lett. 2004;150:85-96.
194. Levi M, Guchelaar HJ, Woerdenbag, Zhu YP. Acute hepatitis in a patient using a Chinese herbal tea: a case report. Pharmacy World Sci. 1998;20:43-44.
195. Kao WF, Hung DZ, Tsai WJ, Lin KP, Deng JF. Podophyllotoxin intoxication: toxic effects of bajiaolian in herbal therapeutics. Hum Exp Toxicol. 1992;11:480-487.
196. Whiting PW, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust. 2002;177:440-443.
197. Nadir A, Reddy D, Van Thiel DH. Cascara sagrada-induced intrahepatic cholestasis causing portal hypertension: case report and review of herbal hepatotoxicity. Am J Gastroenterol. 2000; 95:3634-3637.
198. Benninger J, Schneider HT, Schuppan D, Kirchner T, Hahn EG. Acute hepatitis induced by greater celandine (Chelidonium majus). Gastroenterology. 1999;117:1234-1237.
199. Sheikh NM, Philen RM, Love LA. Chaparral-associated hepato-toxicity. Arch Intern Med. 1997;157:913-919.
200. Grant KL, Boyer LV, Erdman.BE. Chaparral-induced hepato-toxicity. Integrative Med. 1998;1:83-87.
201. Vautier G, Spiller RC. Safety of complementary medicines should be monitored. BMJ. 1995;311:633.
202. Castot A, Larrey D. Acute hepatitis following administration of germander-containing products: 26 cases. Gastroenterol Clin Biol. 1992;16:916-922.
203. Willett KL, Roth RA, Walker L. Workshop overview: hepatotoxicity assessment for botanical dietary supplements. Toxicol Sci. 2004;79:4-9.
204. Nadir A, Agrawal S, King PD, Marshall JB. Acute hepatitis associated with the use of a Chinese herbal product ma-huang. Am J Gastroenterol. 1996;91:1436-1438.
205. Anderson IB, Mullen WH, Meeker JE, et al. Pennyroyal toxicity measurement of toxic metabolite levels in two cases and review of the literature. Ann Intern Med. 1996;124:726-734.
206. Pearson W. Pyrrolizidine alkaloids in higher plants: hepatic veno-occlusive disease associated with chronic consumption. J Neutraceuticals. 2000;3:87-96.
207. Angell M, Kassirer JP. Alternative medicine: the risks of untested and unregulated remedies. N Engl J Med. 1998;339: 839.
208. Ko RJ. Adulterants in Asian patent medicines. N Engl J Med. 1998;339:847.
209. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet. 2000;355:548.
210. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, 'Falloon J. Indinavir concentrations and St. John's wort. Lancet. 2000;355:547-548. Erratum in Lancet 2001;357:1210.
211. Brewer GJ. Zinc acetate for the treatment of Wilson's disease. Expert Opin Pharmacother. 2001;2:1473-1477.
212. Miller ER 3rd, Pastor-Barriuso R, Dalai D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37-46.